MA46731B1 - Anticorps anti-tmprss2 et fragments de liaison à l'antigène - Google Patents
Anticorps anti-tmprss2 et fragments de liaison à l'antigèneInfo
- Publication number
- MA46731B1 MA46731B1 MA46731A MA46731A MA46731B1 MA 46731 B1 MA46731 B1 MA 46731B1 MA 46731 A MA46731 A MA 46731A MA 46731 A MA46731 A MA 46731A MA 46731 B1 MA46731 B1 MA 46731B1
- Authority
- MA
- Morocco
- Prior art keywords
- antigen binding
- binding fragments
- tmprss2 antibodies
- tmprss2
- antibodies
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention comprend un anticorps ou un fragment de liaison à l'antigène de celui-ci qui se lie spécifiquement à tmprss2 et des procédés d'utilisation de tels anticorps et fragments pour traiter ou prévenir des infections virales (par exemple, des infections par le virus de la grippe).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862622292P | 2018-01-26 | 2018-01-26 | |
PCT/US2019/014978 WO2019147831A1 (fr) | 2018-01-26 | 2019-01-24 | Anticorps anti-tmprss2 et fragments de liaison à l'antigène |
Publications (2)
Publication Number | Publication Date |
---|---|
MA46731A MA46731A (fr) | 2020-04-22 |
MA46731B1 true MA46731B1 (fr) | 2021-06-30 |
Family
ID=66102175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA46731A MA46731B1 (fr) | 2018-01-26 | 2019-01-24 | Anticorps anti-tmprss2 et fragments de liaison à l'antigène |
Country Status (25)
Country | Link |
---|---|
US (3) | US10941213B2 (fr) |
EP (1) | EP3638698B1 (fr) |
JP (2) | JP2021511058A (fr) |
KR (1) | KR20200115576A (fr) |
CN (1) | CN111936517A (fr) |
AU (1) | AU2019211406A1 (fr) |
BR (1) | BR112020015112A2 (fr) |
CA (1) | CA3089377A1 (fr) |
CY (1) | CY1124182T1 (fr) |
DK (1) | DK3638698T3 (fr) |
ES (1) | ES2864529T3 (fr) |
HR (1) | HRP20210876T1 (fr) |
HU (1) | HUE054403T2 (fr) |
IL (1) | IL276164A (fr) |
LT (1) | LT3638698T (fr) |
MA (1) | MA46731B1 (fr) |
MD (1) | MD3638698T2 (fr) |
MX (1) | MX2020007888A (fr) |
PL (1) | PL3638698T3 (fr) |
PT (1) | PT3638698T (fr) |
RS (1) | RS61825B1 (fr) |
SG (1) | SG11202006898TA (fr) |
SI (1) | SI3638698T1 (fr) |
WO (1) | WO2019147831A1 (fr) |
ZA (1) | ZA202004494B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
KR20220069046A (ko) * | 2019-09-23 | 2022-05-26 | 트위스트 바이오사이언스 코포레이션 | 단일 도메인 항체에 대한 변이체 핵산 라이브러리 |
MX2022009476A (es) * | 2020-02-10 | 2022-08-22 | Regeneron Pharma | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. |
WO2021190980A1 (fr) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimères pour l'évolution d'une souche virale |
PE20221893A1 (es) | 2020-04-02 | 2022-12-13 | Regeneron Pharma | Anticuerpos contra glicoproteina de espicula anti-sars-cov-2 y fragmentos de union al antigeno |
KR20230002612A (ko) * | 2020-04-13 | 2023-01-05 | 매든 어드바이저스 엘엘씨 | Ace2-표적화 조성물 및 covid-19의 치료 방법 |
CN116075725A (zh) | 2020-04-17 | 2023-05-05 | 瑞泽恩制药公司 | 用于冠状病毒中和抗体的检测测定法 |
US20230149536A1 (en) | 2020-04-17 | 2023-05-18 | Vyriad, Inc. | Compositions for treating and/or preventing coronavirus infections |
AU2021282179A1 (en) | 2020-05-26 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
US20210379091A1 (en) * | 2020-06-08 | 2021-12-09 | Brigham Young University | Use of cationic steroidal antimicrobial compounds to deactivate coronavirus |
WO2021255217A1 (fr) | 2020-06-19 | 2021-12-23 | Heidelberg Pharma Research Gmbh | Amatoxine et conjugués d'amatoxine destinés à être utilisés dans l'inhibition de la réplication de virus à arn |
CN111986818A (zh) * | 2020-08-21 | 2020-11-24 | 南通大学 | 一种基于tmprss2的新冠covid-19治疗药物筛选系统 |
CN112795583A (zh) * | 2020-11-16 | 2021-05-14 | 上海大学 | 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法 |
WO2022115503A1 (fr) | 2020-11-25 | 2022-06-02 | Dupont Nutrition Biosciences Aps | Traitement et prévention d'une infection à coronavirus |
CN112538494A (zh) * | 2020-12-08 | 2021-03-23 | 武汉华美生物工程有限公司 | 一种tmprss2突变体蛋白及其表达载体、表达工程菌和制备方法 |
WO2022133182A1 (fr) * | 2020-12-18 | 2022-06-23 | Chan Zuckerberg Biohub, Inc. | Procédé de traitement d'une infection au coronavirus |
WO2022184659A1 (fr) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Domaines d'anticorps et multimères |
WO2022187626A1 (fr) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anticorps de glycoprotéine anti-sars-cov-2 à variante spike et fragments de liaison à l'antigène |
US20230125469A1 (en) | 2021-07-14 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments |
WO2023199943A1 (fr) * | 2022-04-12 | 2023-10-19 | 国立研究開発法人理化学研究所 | Anticorps utilisé pour traiter une infection à coronavirus |
WO2023220712A1 (fr) * | 2022-05-13 | 2023-11-16 | The Trustees Of Columbia University In The City Of New York | Protéases hôtes essentielles pour la propagation de parainfluenza dans le poumon humain : cibles potentielles pour interventions antivirales |
CN116003611B (zh) * | 2022-08-17 | 2024-02-27 | 中南大学湘雅医院 | 抗tmprss2抗体及其用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
WO1993004169A1 (fr) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques |
CA2415923C (fr) | 2000-07-12 | 2011-10-25 | Agensys, Inc. | Nouvel antigene tumoral utile dans le diagnostic et le traitement de cancers de la vessie, de l'ovaire, du poumon et du rein |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US8354508B2 (en) | 2006-07-21 | 2013-01-15 | Diadexus, Inc. | PRO115 antibody compositions and methods of use |
EP2057191A1 (fr) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6 |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
CN102099378B (zh) | 2008-05-16 | 2016-01-20 | 埃博灵克斯股份有限公司 | 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽 |
ES2707599T3 (es) * | 2012-01-31 | 2019-04-04 | Regeneron Pharma | Anticuerpos anti-asic1 y usos de los mismos |
NZ631105A (en) * | 2012-04-16 | 2016-09-30 | Regeneron Pharma | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
JP2020514396A (ja) * | 2017-03-22 | 2020-05-21 | ザ チルドレンズ メディカル センター コーポレーション | Lrp1結合剤およびその使用 |
-
2019
- 2019-01-24 MX MX2020007888A patent/MX2020007888A/es unknown
- 2019-01-24 WO PCT/US2019/014978 patent/WO2019147831A1/fr unknown
- 2019-01-24 CA CA3089377A patent/CA3089377A1/fr active Pending
- 2019-01-24 EP EP19701428.5A patent/EP3638698B1/fr active Active
- 2019-01-24 MD MDE20200454T patent/MD3638698T2/ro unknown
- 2019-01-24 KR KR1020207024526A patent/KR20200115576A/ko active Search and Examination
- 2019-01-24 PT PT197014285T patent/PT3638698T/pt unknown
- 2019-01-24 SG SG11202006898TA patent/SG11202006898TA/en unknown
- 2019-01-24 SI SI201930061T patent/SI3638698T1/sl unknown
- 2019-01-24 RS RS20210571A patent/RS61825B1/sr unknown
- 2019-01-24 AU AU2019211406A patent/AU2019211406A1/en active Pending
- 2019-01-24 HU HUE19701428A patent/HUE054403T2/hu unknown
- 2019-01-24 JP JP2020540397A patent/JP2021511058A/ja active Pending
- 2019-01-24 ES ES19701428T patent/ES2864529T3/es active Active
- 2019-01-24 LT LTEP19701428.5T patent/LT3638698T/lt unknown
- 2019-01-24 US US16/256,560 patent/US10941213B2/en active Active
- 2019-01-24 PL PL19701428T patent/PL3638698T3/pl unknown
- 2019-01-24 CN CN201980021929.3A patent/CN111936517A/zh active Pending
- 2019-01-24 MA MA46731A patent/MA46731B1/fr unknown
- 2019-01-24 DK DK19701428.5T patent/DK3638698T3/da active
- 2019-01-24 BR BR112020015112-2A patent/BR112020015112A2/pt unknown
-
2020
- 2020-07-20 IL IL276164A patent/IL276164A/en unknown
- 2020-07-21 ZA ZA2020/04494A patent/ZA202004494B/en unknown
-
2021
- 2021-01-20 US US17/153,684 patent/US11603413B2/en active Active
- 2021-05-27 CY CY20211100461T patent/CY1124182T1/el unknown
- 2021-06-01 HR HRP20210876TT patent/HRP20210876T1/hr unknown
-
2023
- 2023-01-26 US US18/159,827 patent/US20230265216A1/en active Pending
- 2023-10-13 JP JP2023177262A patent/JP2024009962A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111936517A (zh) | 2020-11-13 |
PL3638698T3 (pl) | 2021-09-06 |
JP2021511058A (ja) | 2021-05-06 |
WO2019147831A1 (fr) | 2019-08-01 |
SG11202006898TA (en) | 2020-08-28 |
KR20200115576A (ko) | 2020-10-07 |
LT3638698T (lt) | 2021-04-12 |
MA46731A (fr) | 2020-04-22 |
PT3638698T (pt) | 2021-04-06 |
JP2024009962A (ja) | 2024-01-23 |
ES2864529T3 (es) | 2021-10-14 |
EP3638698B1 (fr) | 2021-03-03 |
EP3638698A1 (fr) | 2020-04-22 |
US10941213B2 (en) | 2021-03-09 |
ZA202004494B (en) | 2022-05-25 |
IL276164A (en) | 2020-09-30 |
CA3089377A1 (fr) | 2019-08-01 |
US11603413B2 (en) | 2023-03-14 |
BR112020015112A2 (pt) | 2021-04-06 |
MX2020007888A (es) | 2020-09-07 |
DK3638698T3 (da) | 2021-04-26 |
HRP20210876T1 (hr) | 2021-07-09 |
US20190300625A1 (en) | 2019-10-03 |
SI3638698T1 (sl) | 2021-07-30 |
HUE054403T2 (hu) | 2021-09-28 |
RS61825B1 (sr) | 2021-06-30 |
US20210230303A1 (en) | 2021-07-29 |
US20220081489A9 (en) | 2022-03-17 |
US20230265216A1 (en) | 2023-08-24 |
MD3638698T2 (ro) | 2021-07-31 |
AU2019211406A1 (en) | 2020-08-13 |
CY1124182T1 (el) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46731A (fr) | Anticorps anti-tmprss2 et fragments de liaison à l'antigène | |
MA54405B1 (fr) | Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène | |
MA40476A (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
CR20200579A (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
MA40474A (fr) | Anticorps monoclonal anti-ctla4 ou fragment de celui-ci se liant à l'antigène, composition médicinale et son utilisation | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
WO2021212049A3 (fr) | Anticorps monoclonaux anti-sars-cov-2 | |
MX2022014598A (es) | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. | |
CR20220660A (es) | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 | |
MA54975A1 (fr) | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation | |
EA202191231A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ | |
MX2023005653A (es) | Anticuerpos contra los virus de la influenza a. | |
DK1200126T3 (da) | Anvendelse af CD28-specifikke monoklonale antistoffer til fremstilling af en farmaceutisk sammensætning til behandling af virusinfektioner | |
MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
MX2022002672A (es) | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. | |
CR20220061A (es) | Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células | |
WO2023019174A3 (fr) | Anticorps contre le sars-cov-2 | |
MA53186A1 (fr) | Anticorps monoclonal qui se lie spécifiquement à cd20 | |
MX2022003191A (es) | Terapias de combinacion con anticuerpos entpd2 y cd73. | |
BR112024000744A2 (pt) | Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno | |
MA42186B1 (fr) | Protéines de liaison d'antigène qui activent le récepteur de la leptine | |
EA202190194A1 (ru) | Антитела к видам бактерий рода campylobacter |